The United States Food and Drug Administration (FDA) has granted United Kingdom-based AstraZeneca and United States-based Merck a New Drug Application (NDA) and priority review for the MEK 1/2 inhibitor Selumetinib as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis (NF1) type one and symptomatic, inoperable plexiform neurofibromas (PFs), it was reported on Friday.
This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug User Fee Act (PDUFA) date is scheduled for the second quarter of 2020.
This regulatory submission was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored SPRINT Phase two Stratum one trial. An objective response rate (ORR) was achieved in 66% of paediatric patients with neurofibromatosis type 1 and symptomatic, inoperable PNs (n=33/50 patients) when treated with selumetinib as a twice-daily oral monotherapy. ORR was defined as the percentage of patients with a confirmed complete or partial response of greater than 20% tumour volume reduction.
AstraZeneca and Merck have a strategic collaboration agreement to co-develop and co-commercialize selumetinib globally.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT